Search research articles
Contact Us
Filters
Showing results (121-130 of 193) with videos related to
Page
of 20
Sort By:
Immunobiology
|
June 9, 2016
Chromosomal rearrangement-A rare cause of complement factor I associated atypical haemolytic uraemic syndrome
Patrick J Gleeson, Valerie Wilson, Thomas E Cox, et al.
Kidney International Reports
|
January 15, 2025
Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis
Andrew S Bomback, Erica Daina, Giuseppe Remuzzi, et al.
Journal of the American Society of Nephrology : JASN
|
May 27, 2005
Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome
David Kavanagh, Elizabeth J Kemp, Elizabeth Mayland, et al.
Journal of Medical Case Reports
|
May 1, 2015
Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report
Mustafa Sevinc, Taner Basturk, Tuncay Sahutoglu, et al.
Kidney International
|
December 5, 2020
Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296
Eric Rondeau, Marie Scully, Gema Ariceta, et al.
Blood
|
November 8, 2011
A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome
Nigel J Francis, Bairbre McNicholas, Atif Awan, et al.
Kidney International
|
April 24, 2021
Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296
Eric Rondeau, Marie Scully, Gema Ariceta, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
May 21, 2009
The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome
Viviana P Ferreira, Andrew P Herbert, Claudio Cortés, et al.
Kidney Medicine
|
April 20, 2026
C3 Glomerulonephritis Associated With Anti-complement Factor B Antibodies Following Anti-cancer Treatment With Pembrolizumab
Persia Stroppou, Lucia Asaelof, Alexia Panayides, et al.
Kidney International
|
April 18, 2020
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
Eric Rondeau, Marie Scully, Gema Ariceta, et al.
Page
of 20
Search research articles
Search
Showing results (121-130 of 193) with videos related to
Sort By:
Page
of 20
Immunobiology
|
June 9, 2016
Chromosomal rearrangement-A rare cause of complement factor I associated atypical haemolytic uraemic syndrome
Patrick J Gleeson, Valerie Wilson, Thomas E Cox, et al.
Kidney International Reports
|
January 15, 2025
Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis
Andrew S Bomback, Erica Daina, Giuseppe Remuzzi, et al.
Journal of the American Society of Nephrology : JASN
|
May 27, 2005
Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome
David Kavanagh, Elizabeth J Kemp, Elizabeth Mayland, et al.
Journal of Medical Case Reports
|
May 1, 2015
Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report
Mustafa Sevinc, Taner Basturk, Tuncay Sahutoglu, et al.
Kidney International
|
December 5, 2020
Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296
Eric Rondeau, Marie Scully, Gema Ariceta, et al.
Blood
|
November 8, 2011
A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome
Nigel J Francis, Bairbre McNicholas, Atif Awan, et al.
Kidney International
|
April 24, 2021
Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296
Eric Rondeau, Marie Scully, Gema Ariceta, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
May 21, 2009
The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome
Viviana P Ferreira, Andrew P Herbert, Claudio Cortés, et al.
Kidney Medicine
|
April 20, 2026
C3 Glomerulonephritis Associated With Anti-complement Factor B Antibodies Following Anti-cancer Treatment With Pembrolizumab
Persia Stroppou, Lucia Asaelof, Alexia Panayides, et al.
Kidney International
|
April 18, 2020
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
Eric Rondeau, Marie Scully, Gema Ariceta, et al.
Page
of 20